Pfizer's PFE stock has risen 5% since it reported first-quarter results on April 29. While the company beat estimates for ...

As the state faces a multimillion dollar measles outbreak in West Texas, the House Public Health Committee passes HB 1586 ...

Pfizer said it halted development of danuglipron after discovering that a "participant in one of the dose-optimization studies experienced potential drug-induced liver injury." (REUTERS/Carlo ...

With the company’s Q1 2025 results on Tuesday, Pfizer (NYSE:PFE) indicated plans to explore acquisitions or partnerships to ...

Pfizer said dose-optimization studies of once-daily danuglipron showed that overall frequency of liver enzyme elevations across 1,400 study participants was in line with approved drugs in the class.

Pfizer (PFE) announced the decision to discontinue development of danuglipron, an oral glucagon-like peptide-1 receptor agonist, which was ...

Pfizer’s dose-optimization studies of once-daily formulations of danuglipron (NCT06567327 and NCT06568731) met key pharmacokinetic objectives and confirmed a formulation and dose with the ...

Pfizer took the decision after one of the participants in the dose-optimization studies developed a potentially drug-induced liver injury, which resolved after danuglipron was discontinued.

Pfizer (NYSE:PFE) is overhauling its cardiometabolic pipeline and weighing acquisitions after an oral weight-loss candidate ...